

Covidien Neurovascular Micro Catheter Receives FDA Approval

Apollo™ Onyx™ Delivery Micro Catheter with Detachable Tip Enhances Onyx™ Liquid Embolic System (LES) Delivery

DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 10, 2014--[Covidien plc](#) (NYSE: COV) today announced U.S. Food and Drug Administration (FDA) approval of its Apollo™ Onyx™ delivery micro catheter - the first detachable tip micro catheter available in the U.S. The new micro catheter is designed to mitigate the technical challenges of catheter retrieval during Onyx™LES embolizations of brain arteriovenous malformations (bAVMs).



FDA approves Covidien's Apollo™ Onyx™ delivery micro catheter - the first detachable tip micro catheter available in the U.S. (Photo: Business Wire)

A bAVM occurs when a tangle of blood vessels in the brain or on its surface bypasses normal brain tissue and directly diverts blood from the arteries to the veins. Normally, arteries carry blood containing oxygen from the heart to the brain, and veins carry blood with less oxygen away from the brain and back to the heart. According to the American Heart Association, bAVMs occur in approximately one in 200–500 people and are more common in males than in females.

“This new game-changing device will improve physicians' options for treating patients with bAVMs,” said Dr. Alejandro Berenstein, director, Center for Endovascular Surgery at the Hyman-Newman Institute for Neurology and Neurosurgery at Mount Sinai Health Systems in New York City. “The Apollo Onyx micro catheter provides a very important added safety mechanism for catheter retrieval during Onyx LES embolizations of bAVMs, permitting a more complete treatment in a much safer manner.”

The Apollo Onyx micro catheter enables physicians to choose the best catheter position for each procedure. It provides optimal navigability through complex distal anatomy as well as a proprietary detachable tip designed for easier catheter retrieval in challenging environments.

“Covidien is offering a new level of confidence for physicians by providing the only detachable tip micro catheter in the U.S.,” said Brett Wall, president, Neurovascular, Covidien. “The Apollo Onyx micro catheter has the potential to improve patient outcomes by safeguarding the neurovasculature during catheter retrieval.”

The Apollo Onyx micro catheter will be showcased at the [Society of NeuroInterventional Surgery's \(SNIS\)](#) 11th annual meeting to be held July 28 in Colorado Springs, Colo.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of \$10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.

□

Photos/Multimedia Gallery Available: <http://www.businesswire.com/multimedia/home/20140610006650/en/>

Source: Covidien plc

Covidien plc

David T. Young, 508-452-1644

Manager, External Communications

Vascular Therapies

david.young@covidien.com

or

Cole Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com

or

Peter Lucht, 508-452-4168

Vice President, External Communications

Corporate Communications

peter.lucht@covidien.com

or

Todd Carpenter, 508-452-4363

Senior Director

Investor Relations

todd.carpenter@covidien.com

<https://news.medtronic.com/2014-06-10-Covidien-Neurovascular-Micro-Catheter-Receives-FDA-Approval>